Belimumab prefilled syringe

Belimumab prefilled syringe

Form: Subcutaneous (SC) and intravenous (IV) Prefilled syringe

Strength: 200 mg/ten 1 mL for SQ; 10 mg/mL for IV

Reference Brands: Benlysta(US & EU)

Category: Immune Disorder

Belimumab, marketed as Benlysta, is approved in the US by the FDA and in the EU via EMA for treating active systemic lupus erythematosus (SLE). Regulatory approval requires a comprehensive dossier including clinical trial data, safety profiles, manufacturing processes, and pharmacovigilance plans. In the US, the FDA reviews detailed clinical and manufacturing information, while the EMA ensures regional compliance with safety and quality standards. For guidance on dossier preparation, regulatory pathways, and market access, visit PharmaTradz. Ensuring thorough regulatory compliance is essential for the safe, effective, and timely approval of belimumab prefilled syringe products worldwide, supporting advanced autoimmune disease management.

Get Enquiry Back to Listing
Disclaimer: By continuing to browse, you agree to the terms of use of this website and the Trade Marks displayed, in compliance with the provisions of the Trademark Act, 1999, Section 30 and 30(1) under 'Fair use.'

The Trade Mark owner has been correctly identified under the heading Manufacturer / TM Owner as required by the Act.

Related Products

Anakinra injection

Strength: 100 mg/mL

Form: Injection(SQ)

Reference Brands: Kinerso, Kineret(US)

View Details Get Enquiry
IVIG (Intravenous Immunoglobulin) solution

Strength: 5% or 10%

Form: Intravenous infusion

Reference Brands: Gammagard (Gamunex-C, Flebogamma),Privigen, Octagam, Gamunex-C(US)

View Details Get Enquiry
Ustekinumab Injection

Strength: SQ:: 45 mg, 90 mg; IV: 130 mg/vial

Form: SQ and IV injection

Reference Brands: Stelara(US)

View Details Get Enquiry
Everolimus tablets

Strength: 0.75 mg, 1.25 mg, 2.5 mg, 5 mg, 7.5 mg, 10 mg

Form: Tablet

Reference Brands: Zortress, Afinitor(US & EU)

View Details Get Enquiry

Subscribe to Our Newsletter

Stay updated on pharma trends and marketplace opportunities.